Ovarian

New Study Provides BRCA Mutation Carriers Guidance For When Surgery Has Greatest Impact

(INFORMS) July 19, 2017 – Researchers developed a decision-analytic model that provides a timetable for women who carry BRCA mutations regarding which procedures to undergo, in what order they should be conducted, and at what age they will have the greatest positive impact.

read press release

Why Do BRCA1 Mutations Cause Predominantly Breast And Ovarian Cancer?

(UT Health San Antonio) July 18, 2017 - A discovery, reported June 26 in Nature Communications, is of a new, previously unrecognized function of BRCA1.

read press release

Public Comment on Draft Recommendation Statement and Draft Evidence Review: Screening for Ovarian Cancer

(USPSTF) July 18, 2017 - The U.S. Preventive Services Task Force seeks comments on a draft recommendation statement and draft evidence review on screening for ovarian cancer. After reviewing the evidence, the Task Force recommends against screening for ovarian cancer in asymptomatic women.

read press release

Ovarian Cancer: Statins Might Be Effective With Diet Control

(Medical News Today) July 17, 2017 - Laboratory tests have shown that statins, which are drugs used to control cholesterol, can kill ovarian cancer cells.

read article

ICER Releases Draft Evidence Report Reviewing Olaparib, Rucaparib, and Niraparib for Ovarian Cancer

(ICER) July 12, 2017 - The Institute for Clinical and Economic Review (ICER) has released a Draft Evidence Report assessing the comparative clinical effectiveness and value of three poly ADP-ribose polymerase (PARP) inhibitors for treatment of ovarian cancer: olaparib (Lynparza™, AstraZeneca), rucaparib (Rubraca®, Clovis Oncology), and niraparib (Zejula™, Tesaro).

read press release

Redeeming Qualities For Belly Fat? When It’s Actually The Omentum, Sure

(STAT Plus) July 14, 2017 - The omentum — specifically, its immune cells — may be where researchers need to focus if they want to find new treatments for some stubborn cancers that have spread.

read article (paid subscription required)

FDA Panel Unanimously Backs Avastin and Herceptin Biosimilars

(Regulatory Focus) July 13, 2017 - The US Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) on Thursday unanimously backed the approval of biosimilar versions of two of Roche's top selling cancer drugs, Avastin (bevacizumab) and Herceptin (trastuzumab).

read article

Risk-Reducing Mastectomy Questioned for BRCA Mutation Carriers with Prior Ovarian Cancer

(Duke Health) July 11, 2017 - For the subset of women with BRCA mutations who have already had ovarian cancer, risk-reducing mastectomy might not be worth the price tag.

read press release

Oncology Venture and Eisai Forge Exclusive Global License Agreement for Clinical Stage Oncology Drug PARP Inhibitor E7449/2X-121

(Morningstar) July 7, 2017 - Oncology Venture AB and 2X Oncology Inc., today announced that Oncology Venture has entered into an exclusive global license agreement with Eisai Inc. for Eisai`s Phase 2 PARP inhibitor E7449 - now called 2X-121.

read article

Blood Test By Britain's Angle Detects Ovarian Cancer In Study

(Reuters) July 4, 2017 - British liquid biopsy company Angle said its Parsortix blood test had beaten current methods in identifying ovarian cancer, a breakthough that could help women receive the best possible outcome from surgery.

read article

British Liquid Biopsy for Ovarian Cancer Outperforms the Gold Standard

(Labiotech.eu) July 4, 2017 - The British company Angle has announced results from a large-scale trial that seem to indicate its liquid biopsy technology could surpass the gold standard in ovarian cancer diagnosis.

read article

Time Since Chemotherapy May Predict Response To Olaparib In Ovarian Cancer

(ICR [UK]) June 29, 2017 - Women with advanced ovarian cancer who begin treatment with olaparib are more likely to respond to the drug if it has been more than a year since their last round of chemotherapy, according to new research.

read article

Genetic Tests Help Identify Relative Risk of 25 Cancer-Associated Mutations

(Stanford Medicine) June 27, 2017 - No one wants to hear that they have a mutation in their DNA associated with the development of cancer.

read press release

Most Precise Estimates Ever of Cancer Risks With BRCA

(Medscape Medical News) June 20, 2017 - While it has been well established that carriers of the BRCA1 and BRCA2 mutations face a higher risk for breast and ovarian cancer, most studies to date have been retrospective.

read article (free registration required)

Clovis's Ovarian Cancer Drug Set For Label Expansion, Shares Soar

(Reuters) June 19, 2017 - Positive late-stage data on Clovis Oncology Inc's ovarian cancer drug, Rubraca, could help widen the use of the therapy and differentiate it from rivals, the U.S. biotech said on Monday, sending its shares soaring 48 percent.

read article

New Test May Turn AZ's Lynparza Into Precision Drug For Prostate Cancer

(Reuters) June 18, 2017 - Scientists have developed a new three-in-one blood test that has the potential to turn AstraZeneca's drug Lynparza into a precision medicine for prostate cancer.

read article

Clovis Oncology Stock Surges 50% On Positive Late-Stage Cancer Trial Results

(Marketwatch) June 19, 2017 - Clovis Oncology Inc. shares surged 50% in premarket trade Monday after the company said its late-stage trial for a cancer drug met its primary endpoint and a key secondary endpoint.

read article

New Three-In-One Blood Test Opens Door To Precision Medicine For Prostate Cancer

(ICR [UK]) June 19, 2017 - Scientists have developed a three-in-one blood test that could transform treatment of advanced prostate cancer through use of precision drugs designed to target mutations in the BRCA genes.

read article

Clovis Oncology’s Rucaparib Significantly Improved Progression-Free Survival in All Ovarian Cancer Patient Populations Studied in Phase 3 ARIEL3 Maintenance Treatment Trial

(Morningstar) June 19, 2017 - Clovis Oncology, Inc. today announced topline data from the confirmatory phase 3 ARIEL3 trial of rucaparib, which successfully achieved the primary endpoint of improved progression-free survival (PFS) by investigator review in each of the three populations studied.

read article

When Your Personal War on Cancer Is Exhausting

(New York Times/Well blog) June 8, 2017 - People with cancer talk about battling, fighting, defeating and conquering their disease. But I honor those who decide to lay down arms.

read article
Next Page